We have curated a list of phase 3 clinical trials that have an anticipated completion date in July 2025 in the United States. Once completed, it is required that the results be posted within one year of the primary completion date. These interventional clinical trials hold the promise of transforming treatment protocols for a myriad of conditions, potentially leading to updates of medical guidelines.
9 Phase 3 Clinical Trials Completing in July 2025
| Primary Completion Date | Study Title | Summary | Conditions | Interventions |
|---|---|---|---|---|
| July 25, 2025 | A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients with Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis (ADAPT SERON) | The main objective of this study is measuring the efficacy and safety of Efgartigimod IV compared to placebo in participants with AChR-Ab seronegative generalized myasthenia gravis. | Generalized Myasthenia Gravis | Efgartigimod IV, placebo IV |
| July 25, 2025 | Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC with Detectable ESR1m Before Progression (SERENA-6) | AzD9833 in combination with CDK4/6 inhibitor will be compared with aromatase inhibitors in combination with CDK4/6 inhibitor in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with detectable ESR1 mutation. | ER-Positive HER2-Negative Breast Cancer | AZD9833, AZD9833 placebo, Anastrozole, Anastrozole placebo, Letrozole, Letrozole placebo, Palbociclib, Abemaciclib, Luteinizing hormone-releasing hormone (LHRH) agonist, Ribociclib |
| July 30, 2025 | A Study to Evaluate the Efficacy and Safety of Serplulimab in Combination with Chemotherapy and Concurrent Radiotherapy in Patients with Limited-Stage Small Cell Lung Cancer | The study is comparing the efficacy and safety of Serplulimab and chemotherapy and concurrent radiotherapy vs. chemotherapy and concurrent radiotherapy in patients with limited-stage small cell lung cancer. | Limited-Stage Small Cell Lung Cancer | HLX10, carboplatin/cisplatin-etoposide, thoracic radiotherapy, placebo, prophylactic cranial irradiation |
| July 31, 2025 | Efficacy and Safety of Intravenous Efzofitimod in Patients with Pulmonary Sarcoidosis | This trial is comparing the efficacy and safety of IV efzofitimod 3 mg/kg and 5 mg/kg versus placebo following 48 weeks of treatment. | Pulmonary Sarcoidosis | Efzofitimod 3mg/kg, Efzofitimod 5mg/kg, placebo |
| July 31, 2025 | A Randomized Controlled Trial of Inhaled Tranexamic Acid for the Treatment of Pulmonary Hemorrhage in Cancer Patients | This study examines if inhaled tranexamic acid can improve mortality in patients with cancer-related pulmonary hemorrhage and respiratory failure as compared to usual care. | Pulmonary Hemorrhage, Cancer | Tranexamic acid, usual care |
| July 2025 | Light-Activated Antimicrobial Therapy to Prevent Surgical Site Infections (LANTERN) | The objectives are to compare the efficacy and estimate the safety of applying nasal antimicrobial photodisinfection therapy before surgery in reducing the incidence of surgical site infections within the initial 30 days after surgery compared to the standard of care. | Surgical Site Infections, Surgical Wound Infections, Infections, Anti-Infective Agents | Nasal Antimicrobial Photodisinfection Therapy |
| July 2025 | Study of XL092 + Nivolumab vs Sunitinib in Subjects with Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma (STELLAR-304) | This is a randomized, open-label phase 3 study of XL092 _ Nivolumab vs Sunitinib in subjects with advanced or metastatic non-clear cell renal cell carcinoma. | Non-clear Cell Renal Cell Carcinoma | XL092, Nivolumab, Sunitinib Malate |
| July 2025 | A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age with Chronic Migraine (REBUILD-2) | This trial evaluates the efficacy and safety of galcanezumab for the preventive treatment of chronic migraine in participants who are 12 to 17 years old. | Chronic Migraine | Galcanezumab, placebo |
| July 2025 | A Safety and Efficacy Study Evaluating CTX001 in Subjects with Severe Sickle Cell Disease | This study investigates the safety and efficacy of autologous CRISPR-Cas9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells using CTX001. | Sickle Cell Disease, Hematological Diseases, Hemoglobinopathies | CTX001 |
Be sure to check back for next month’s edition of anticipated clinical trials for August 2025. In the meantime, explore more clinical trials and sign up for alerts to stay up to date with the latest published guidelines and research.
Copyright © 2025 Guideline Central, all rights reserved.